Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

5.55USD
16 Aug 2018
Change (% chg)

$-0.03 (-0.54%)
Prev Close
$5.58
Open
$5.60
Day's High
$5.62
Day's Low
$5.44
Volume
12,591
Avg. Vol
301,728
52-wk High
$19.74
52-wk Low
$5.11

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $253.10
Shares Outstanding(Mil.): 44.80
Dividend: --
Yield (%): --

Financials

  AKAO.OQ Industry Sector
P/E (TTM): -- 99.04 30.20
EPS (TTM): -3.74 -- --
ROI: -94.65 3.31 12.77
ROE: -137.72 2.31 14.92

FDA knocks back Achaogen's drug for bloodstream infection

The U.S. Food and Drug Administration cleared Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, but shares slumped 25 percent as the drug failed to win approval for treating bloodstream infections.

Jun 26 2018

Achaogen's antibiotic gets FDA nod for urinary tract infections

June 26 The U.S. Food and Drug Administration approved Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, the company said on Tuesday.

Jun 26 2018

BRIEF-Achaogen Q1 loss per share $1.06

* ACHAOGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 04 2018

BRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract Infections

* ACHAOGEN ANNOUNCES FDA ADVISORY COMMITTEE VOTED UNANIMOUSLY IN FAVOR OF PLAZOMICIN FOR TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Achaogen Stock Trading Halted Today

* ACHAOGEN STOCK TRADING HALTED TODAY Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Achaogen Says FDA to Review Plazomicin By June 25

* ACHAOGEN ANNOUNCES DATE OF FDA ADVISORY COMMITTEE MEETING FOR PLAZOMICIN

Mar 21 2018

BRIEF-Robert Duggan Reports 14.2 Pct Stake In Achaogen Inc As Of March 12 Compared To A Stake Of 13.2 Pct As Of Dec 6

* ROBERT DUGGAN REPORTS 14.2 PERCENT STAKE IN ACHAOGEN INC AS OF MARCH 12 COMPARED TO A STAKE OF 13.2 PERCENT AS OF DECEMBER 6 -SEC FILING Source text: (http://bit.ly/2DoINbl) Further company coverage:

Mar 14 2018

BRIEF-Achaogen Enters Into New $50 Million Secured Credit Facility With Silicon Valley Bank

* ACHAOGEN ENTERS INTO NEW $50 MILLION SECURED CREDIT FACILITY WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-Achaogen Reports Q4 Loss Per Share $0.98

* ACHAOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 27 2018

Earnings vs. Estimates